Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Sera Prognostics ( (SERA) ) is now available.
On February 10, 2025, Sera Prognostics announced a public offering of its Class A common stock and pre-funded warrants, expecting to raise approximately $50 million. The proceeds are intended to enhance U.S. commercial infrastructure, prepare for EU expansion, and support studies for the PreTRM test, with a potential FDA submission for broader approval.
More about Sera Prognostics
Sera Prognostics, Inc., headquartered in Salt Lake City, Utah, is a health diagnostics company focused on precision pregnancy care. The company aims to improve maternal and neonatal health through innovative biomarker information, primarily offering products such as the PreTRM Test, which predicts the risk of preterm birth.
YTD Price Performance: -51.62%
Average Trading Volume: 118,598
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $150.3M
Learn more about SERA stock on TipRanks’ Stock Analysis page.